JP2022552714A - 近視治療のためのデジタル装置及びアプリケーション - Google Patents
近視治療のためのデジタル装置及びアプリケーション Download PDFInfo
- Publication number
- JP2022552714A JP2022552714A JP2022523130A JP2022523130A JP2022552714A JP 2022552714 A JP2022552714 A JP 2022552714A JP 2022523130 A JP2022523130 A JP 2022523130A JP 2022523130 A JP2022523130 A JP 2022523130A JP 2022552714 A JP2022552714 A JP 2022552714A
- Authority
- JP
- Japan
- Prior art keywords
- digital
- myopia
- task
- user
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004379 myopia Effects 0.000 title claims abstract description 128
- 208000001491 myopia Diseases 0.000 title claims abstract description 128
- 239000003814 drug Substances 0.000 claims abstract description 59
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 46
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 42
- 230000003950 pathogenic mechanism Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 40
- 230000002182 neurohumoral effect Effects 0.000 claims description 32
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 22
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 20
- 230000004424 eye movement Effects 0.000 claims description 18
- 230000008506 pathogenesis Effects 0.000 claims description 17
- 230000006399 behavior Effects 0.000 claims description 16
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 12
- 102000013275 Somatomedins Human genes 0.000 claims description 12
- 229960003638 dopamine Drugs 0.000 claims description 11
- 229960000890 hydrocortisone Drugs 0.000 claims description 10
- 230000035882 stress Effects 0.000 claims description 10
- 230000008451 emotion Effects 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 7
- 230000019771 cognition Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 230000010534 mechanism of action Effects 0.000 claims description 3
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000004329 axial myopia Effects 0.000 description 37
- 238000013480 data collection Methods 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000010586 diagram Methods 0.000 description 16
- 230000015654 memory Effects 0.000 description 16
- 230000008569 process Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000004515 progressive myopia Effects 0.000 description 9
- 238000004891 communication Methods 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000004402 high myopia Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010073286 Pathologic myopia Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004323 axial length Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004399 eye closure Effects 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000004338 index myopia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004398 oculomotor muscle Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 230000004331 refractive myopia Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000004341 simple myopia Effects 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/113—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for determining or recording eye movement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1118—Determining activity level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H5/00—Exercisers for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
- G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
- G06F3/011—Arrangements for interaction with the human body, e.g. for user immersion in virtual reality
- G06F3/013—Eye tracking input arrangements
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
- G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
- G06F3/017—Gesture based interaction, e.g. based on a set of recognized hand gestures
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
- G09B19/003—Repetitive work cycles; Sequence of movements
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0107—Constructive details modular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5007—Control means thereof computer controlled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5043—Displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0027—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the hearing sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Theoretical Computer Science (AREA)
- Business, Economics & Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Data Mining & Analysis (AREA)
- Human Computer Interaction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Databases & Information Systems (AREA)
- Ophthalmology & Optometry (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Educational Technology (AREA)
- Pain & Pain Management (AREA)
- Educational Administration (AREA)
- Entrepreneurship & Innovation (AREA)
- Anesthesiology (AREA)
- General Business, Economics & Management (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Radiology & Medical Imaging (AREA)
Abstract
Description
本発明は、近視進行の抑制を含む近視治療を目的とするデジタル治療剤(digital therapeutics、以下、DTx)に関し、特に、近視の発病機序を見つけるための基礎科学的論文と関連臨床試験論文に対する文献調査と専門家レビューを通じて、児童期/青少年期の軸性近視に対する発病機序(mechanism of action、以下、MOA)を導出し、これに基づいて児童期/青少年期の軸性近視進行の抑制と治療のための治療仮説(therapeutic hypothesis)とデジタル治療仮説(digital therapeutic hypothesis)を確立することを含む。
010 デジタル課題生成部
020 センシングデータ収集部
030 実行入力部
040 結果分析部
050 データベース
060 保安部
600 デジタル近視治療装置
610 CPU
620 メモリー
630 入出力I/F
640 通信I/F
Claims (20)
- 近視に対する発病機序(mechanism of action、MOA)と治療仮説(hypothesis)に基づいて、前記近視治療のためのデジタル治療剤モジュールを生成し、該デジタル治療剤モジュールに基づいて、具体化したデジタル課題を生成し、前記デジタル課題を第1使用者に提供するデジタル課題生成部と、
前記デジタル課題に対する前記第1使用者の実行結果を収集する結果収集部と、を含む近視治療のためのデジタル装置。 - 前記デジタル課題生成部は、前記近視に対する神経体液性因子に基づいて、前記デジタル治療剤モジュールを生成する、請求項1に記載の近視治療のためのデジタル装置。
- 前記神経体液性因子は、IGF(insulin-like growth factor)、コルチゾール(cortisol)、及びドーパミン(dopamine)を含む、請求項2に記載の近視治療のためのデジタル装置。
- 前記デジタル課題生成部は、第2使用者からの入力に基づいて、前記デジタル治療剤モジュールを生成する、請求項1に記載の近視治療のためのデジタル装置。
- 前記デジタル課題生成部は、前記第1使用者から受信した情報に基づいて、前記デジタル治療剤モジュールを生成する、請求項1に記載の近視治療のためのデジタル装置。
- 前記第1使用者から受信した情報は、前記第1使用者の基底要因、医療情報、及びデジタル治療剤理解能力の少なくともいずれか一つを含み、
前記基底要因は、前記第1使用者の活動量(activity)、心拍数、睡眠、及び食事(栄養と熱量)を含み、
前記医療情報は、前記第1使用者のEMR(electronic medical record)、家族力、遺伝的脆弱性(genetic vulnerability)、及び遺伝的感受性(genetic susceptibility)を含み、
前記デジタル治療剤理解能力は、デジタル治療剤及び装置に関する前記第1使用者の接近性と収容姿勢を含む、請求項5に記載の近視治療のためのデジタル装置。 - 前記デジタル課題生成部は、前記近視に対する発病機序と治療仮説に対して仮想媒介変数を適用して前記デジタル治療剤モジュールを生成する、請求項1に記載の近視治療のためのデジタル装置。
- 前記仮想媒介変数は、前記第1使用者の環境、行動、情緒、及び認知に関して導出される、請求項7に記載の近視治療のためのデジタル装置。
- 前記デジタル課題生成部は、光刺激、眼球運動、ストレス減少、及び成就の少なくとも一つに対応するデジタル治療剤モジュールと当該デジタル課題を生成する、請求項1に記載の近視治療のためのデジタル装置。
- 前記光刺激に対するデジタル課題は、前記第1使用者の光環境を制御することを含む、請求項9に記載の近視治療のためのデジタル装置。
- 前記眼球運動に対するデジタル課題は、前記第1使用者の患者の眼球運動、バイオフィードバック(biofeedback)、眼球関連行動制御の少なくとも一つを含む、請求項9に記載の近視治療のためのデジタル装置。
- 前記ストレス減少に対するデジタル課題は、前記第1使用者の身体運動、自我、安全・平安、楽しさモジュールに関する課題の少なくとも一つを含む、請求項9に記載の近視治療のためのデジタル装置。
- 前記成就に対するデジタル課題は、前記第1使用者に課業成就課題と前記デジタル課題実行に対する補償を提供する課題を含む、請求項9に記載の近視治療のためのデジタル装置。
- 前記結果収集部は、前記デジタル課題に対する前記第1使用者の順守度をモニタリングするか、前記デジタル課題に対して前記第1使用者が直接入力するようにすることにより、前記デジタル課題に対する実行結果を収集する、請求項1に記載の近視治療のためのデジタル装置。
- 前記デジタル課題生成部による前記デジタル課題の生成と、前記結果収集部による前記第1使用者の前記デジタル課題実行結果の収集は、フィードバックループによって複数回繰り返して実行され、
前記デジタル課題生成部は、以前回次で提供された前記第1使用者のデジタル課題と、前記結果収集部によって収集された前記第1使用者の前記デジタル課題に対する実行結果データに基づいて、現在回次に対する前記第1使用者のデジタル課題を生成する、請求項1に記載の近視治療のためのデジタル装置。 - 近視に対する発病機序と治療仮説に基づいて、前記近視治療のためのデジタル治療剤モジュールを生成する段階と、
前記デジタル治療剤モジュールに基づいて、具体化したデジタル課題を生成する段階と、
前記デジタル課題を第1使用者に提供する段階と、
前記デジタル課題に対する前記第1使用者の実行結果を収集する段階と、を含む動作をコンピューティング装置で実行するようにするコンピュータ読み取り可能媒体に格納された近視治療のためのデジタルアプリケーション。 - 前記デジタル治療剤モジュールを生成する段階は、前記近視に対する神経体液性因子に基づいて、前記デジタル治療剤モジュールを生成する、請求項16に記載のコンピュータ読み取り可能媒体に格納された近視治療のためのデジタルアプリケーション。
- 前記デジタル治療剤モジュールを生成する段階は、前記近視に対する発病機序と治療仮説に対して、前記第1使用者の環境、行動、情緒、及び認知に関する仮想媒介変数を適用して前記デジタル治療剤モジュールを生成する、請求項16に記載のコンピュータ読み取り可能媒体に格納された近視治療のためのデジタルアプリケーション。
- 前記デジタル課題を生成する段階は、光刺激、運動、ストレス減少、及び成就の少なくとも一つに対するデジタル課題を生成する、請求項16に記載のコンピュータ読み取り可能媒体に格納された近視治療のためのデジタルアプリケーション。
- 前記デジタル課題を生成する段階と、前記デジタル課題に対する前記第1使用者の実行結果を収集する段階は、フィードバックループによって複数回繰り返して実行され、
前記デジタル課題を生成する段階は、以前回次で提供された前記第1使用者のデジタル課題と、収集された前記第1使用者の前記デジタル課題に対する実行結果データに基づいて、現在回次に対する前記第1使用者のデジタル課題を生成する、請求項16に記載のコンピュータ読み取り可能媒体に格納された近視治療のためのデジタルアプリケーション。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024018329A JP2024055900A (ja) | 2019-10-18 | 2024-02-09 | 近視治療のためのデジタルシステム、デジタルシステムの動作方法及びコンピュータ読み取り可能媒体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190130146A KR102250775B1 (ko) | 2019-10-18 | 2019-10-18 | 근시 치료를 위한 디지털 장치 및 애플리케이션 |
KR10-2019-0130146 | 2019-10-18 | ||
PCT/KR2019/018729 WO2021075641A1 (ko) | 2019-10-18 | 2019-12-30 | 근시 치료를 위한 디지털 장치 및 애플리케이션 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024018329A Division JP2024055900A (ja) | 2019-10-18 | 2024-02-09 | 近視治療のためのデジタルシステム、デジタルシステムの動作方法及びコンピュータ読み取り可能媒体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022552714A true JP2022552714A (ja) | 2022-12-19 |
JPWO2021075641A5 JPWO2021075641A5 (ja) | 2023-06-26 |
JP7437496B2 JP7437496B2 (ja) | 2024-02-22 |
Family
ID=75490934
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022523130A Active JP7437496B2 (ja) | 2019-10-18 | 2019-12-30 | 近視治療のためのデジタルシステム、デジタルシステムの動作方法及びコンピュータ読み取り可能媒体 |
JP2022572792A Pending JP2023531871A (ja) | 2019-10-18 | 2021-04-16 | 近視治療のためのデジタル装置およびアプリケーション |
JP2024018329A Pending JP2024055900A (ja) | 2019-10-18 | 2024-02-09 | 近視治療のためのデジタルシステム、デジタルシステムの動作方法及びコンピュータ読み取り可能媒体 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022572792A Pending JP2023531871A (ja) | 2019-10-18 | 2021-04-16 | 近視治療のためのデジタル装置およびアプリケーション |
JP2024018329A Pending JP2024055900A (ja) | 2019-10-18 | 2024-02-09 | 近視治療のためのデジタルシステム、デジタルシステムの動作方法及びコンピュータ読み取り可能媒体 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20210118322A1 (ja) |
EP (2) | EP4047617A4 (ja) |
JP (3) | JP7437496B2 (ja) |
KR (2) | KR102250775B1 (ja) |
CN (1) | CN115699194A (ja) |
TW (1) | TW202205311A (ja) |
WO (2) | WO2021075641A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220167941A (ko) | 2021-06-15 | 2022-12-22 | 한송욱 | 디지털 치료 장치 및 방법 |
KR20230053787A (ko) | 2021-10-14 | 2023-04-24 | 재단법인 아산사회복지재단 | 소아 근시 진행 예측 모델의 구축 장치 및 예측 모델을 이용한 근시 진행 예측 장치, 방법 및 프로그램 |
KR20230149384A (ko) | 2022-04-19 | 2023-10-27 | 단국대학교 천안캠퍼스 산학협력단 | 메타버스를 이용한 디지털치료제 및 의료기기 사용 적합성 평가시스템 및 방법 |
KR102661561B1 (ko) * | 2023-08-22 | 2024-04-29 | 주식회사 힐링사운드 | 블록체인 기반 건강관리 플랫폼 제공 시스템 및 방법 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1432348A (zh) * | 2002-01-08 | 2003-07-30 | 孟晓静 | 一种矫正发育性近视的方法及装置 |
KR20060006805A (ko) * | 2003-04-11 | 2006-01-19 | 보오슈 앤드 롬 인코포레이팃드 | 시력 교정을 위한 치료 계획에 관한 방법, 시스템 및알고리즘 |
JP2016529963A (ja) * | 2013-07-23 | 2016-09-29 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 非眼光生物学的刺激 |
CN107595308A (zh) * | 2017-08-29 | 2018-01-19 | 中科院合肥技术创新工程院 | 一种眼外肌运动功能评估与训练系统 |
JP2018509983A (ja) * | 2015-03-16 | 2018-04-12 | マジック リープ,インコーポレイティド | 健康を損う疾病を診断して治療する方法及びシステム |
US20180121608A1 (en) * | 2016-11-03 | 2018-05-03 | RightEye, LLC | Systems and methods for a web platform hosting multiple assessments of human visual performance |
WO2019067779A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Miami | DIGITAL THERAPEUTIC GUARANTEES |
JP2020522363A (ja) * | 2017-06-08 | 2020-07-30 | ドパビジョン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 視神経を刺激するためのシステム及び方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6654724B1 (en) * | 1999-02-12 | 2003-11-25 | Adheris, Inc. | System for processing pharmaceutical data while maintaining patient confidentially |
AU6391000A (en) * | 1999-07-28 | 2001-02-19 | Genentech Inc. | Method of preventing the injury or death of retinal cells and treating ocular diseases |
AU2587601A (en) * | 1999-12-22 | 2001-07-03 | Allen, Merrill J. | System for exercising eye muscles |
JP2002058744A (ja) * | 2000-08-21 | 2002-02-26 | Yukihiko Takahashi | 精神障害/疲労回復支援ソフトウエアおよびシステム |
US7033025B2 (en) * | 2002-05-17 | 2006-04-25 | Virtocc, Inc. | Interactive occlusion system |
AU2002952682A0 (en) * | 2002-11-14 | 2002-11-28 | Queensland University Of Technology | A Method or Apparatus for Inhibiting Myopia Developement in Humans |
US7033026B2 (en) * | 2003-07-04 | 2006-04-25 | Spector Robert T | Method of and apparatus for diagnosing and treating amblyopic conditions in the human visual system |
KR100575090B1 (ko) | 2003-12-05 | 2006-05-02 | 김현애 | 입체영상을 이용한 시력 강화 방법 및 그를 실행시키기위한 프로그램을 기록한 컴퓨터로 읽을 수 있는 기록매체 |
KR100692319B1 (ko) | 2006-02-20 | 2007-03-12 | 한국생명공학연구원 | 단백질 상호작용 네트워크 분석을 통한 새로운 질병관련유전자 선정방법 |
US20080077437A1 (en) * | 2006-07-25 | 2008-03-27 | Novavision, Inc. | Process and Method for Providing Incentives to Increase Vision-Therapy Performance |
JP2010148737A (ja) | 2008-12-25 | 2010-07-08 | Panasonic Corp | 視力改善訓練装置および視力改善訓練制御プログラム |
US8002409B2 (en) | 2009-07-14 | 2011-08-23 | Hon Kong Applied Science and Technology Research Institute Co., Ltd. | Vision treatment procedures and devices |
US20140055337A1 (en) * | 2012-08-22 | 2014-02-27 | Mobitv, Inc. | Device eye tracking calibration |
KR101501546B1 (ko) | 2012-12-28 | 2015-03-12 | 문의연 | 순차적 영상 전송을 통한 시력 강화 운동 서비스 제공 방법 |
US9392129B2 (en) * | 2013-03-15 | 2016-07-12 | John Castle Simmons | Light management for image and data control |
KR20150111011A (ko) * | 2014-03-24 | 2015-10-05 | 경북대학교 산학협력단 | 의료 정보 제공 시스템 |
KR101670667B1 (ko) * | 2015-03-04 | 2016-11-09 | 연세대학교 원주산학협력단 | 양안시 개선 장치 |
BR112017019441A2 (pt) | 2015-03-24 | 2018-05-02 | Ares Trading S.A. | sistema de cuidado ao paciente |
RU2580306C1 (ru) * | 2015-03-26 | 2016-04-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ прогнозирования риска развития первичной открытоугольной глаукомы у индивидуумов в зависимости от наличия/отсутствия сопутствующих неинфекционных заболеваний глаз |
CN107438790A (zh) * | 2015-04-10 | 2017-12-05 | 埃西勒国际通用光学公司 | 头戴式显示设备 |
US10912456B2 (en) | 2016-01-27 | 2021-02-09 | Johnson & Johnson Vision Care, Inc. | Ametropia treatment tracking methods and system |
US10042181B2 (en) | 2016-01-27 | 2018-08-07 | Johnson & Johnson Vision Care, Inc. | Ametropia treatment tracking methods and system |
CA3020390A1 (en) | 2016-04-08 | 2017-10-12 | Vizzario, Inc. | Methods and systems for obtaining, aggregating, and analyzing vision data to assess a person's vision performance |
KR101899405B1 (ko) * | 2016-11-11 | 2018-09-17 | 주식회사 3디나라 | 컴퓨터 및 스마트폰을 기반으로 한 시력강화 소프트웨어 구현 방법 |
KR101924125B1 (ko) | 2016-12-23 | 2018-11-30 | 부산대학교 산학협력단 | 클라우드 기반의 안질환 헬스케어 플랫폼 장치 |
IL258706A (en) | 2017-04-25 | 2018-06-28 | Johnson & Johnson Vision Care | Treatment follow-up methods in emmetropia and system |
KR101938136B1 (ko) * | 2017-09-22 | 2019-04-11 | 주식회사 한샘 | 피보호자의 건강관리 통합 솔루션 제공 시스템 |
-
2019
- 2019-10-18 KR KR1020190130146A patent/KR102250775B1/ko active IP Right Grant
- 2019-12-30 EP EP19949074.9A patent/EP4047617A4/en active Pending
- 2019-12-30 JP JP2022523130A patent/JP7437496B2/ja active Active
- 2019-12-30 WO PCT/KR2019/018729 patent/WO2021075641A1/ko unknown
-
2020
- 2020-01-21 US US16/747,980 patent/US20210118322A1/en not_active Abandoned
- 2020-05-26 US US16/883,369 patent/US11189192B2/en active Active
-
2021
- 2021-04-15 TW TW110113641A patent/TW202205311A/zh unknown
- 2021-04-16 EP EP21812866.8A patent/EP4158645A4/en active Pending
- 2021-04-16 CN CN202180040371.0A patent/CN115699194A/zh active Pending
- 2021-04-16 WO PCT/KR2021/004800 patent/WO2021241884A1/en unknown
- 2021-04-16 KR KR1020227041376A patent/KR20230005909A/ko active Search and Examination
- 2021-04-16 JP JP2022572792A patent/JP2023531871A/ja active Pending
- 2021-11-22 US US17/532,324 patent/US20220084432A1/en active Pending
-
2024
- 2024-02-09 JP JP2024018329A patent/JP2024055900A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1432348A (zh) * | 2002-01-08 | 2003-07-30 | 孟晓静 | 一种矫正发育性近视的方法及装置 |
KR20060006805A (ko) * | 2003-04-11 | 2006-01-19 | 보오슈 앤드 롬 인코포레이팃드 | 시력 교정을 위한 치료 계획에 관한 방법, 시스템 및알고리즘 |
JP2016529963A (ja) * | 2013-07-23 | 2016-09-29 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 非眼光生物学的刺激 |
JP2018509983A (ja) * | 2015-03-16 | 2018-04-12 | マジック リープ,インコーポレイティド | 健康を損う疾病を診断して治療する方法及びシステム |
US20180121608A1 (en) * | 2016-11-03 | 2018-05-03 | RightEye, LLC | Systems and methods for a web platform hosting multiple assessments of human visual performance |
JP2020522363A (ja) * | 2017-06-08 | 2020-07-30 | ドパビジョン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 視神経を刺激するためのシステム及び方法 |
CN107595308A (zh) * | 2017-08-29 | 2018-01-19 | 中科院合肥技术创新工程院 | 一种眼外肌运动功能评估与训练系统 |
WO2019067779A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Miami | DIGITAL THERAPEUTIC GUARANTEES |
Also Published As
Publication number | Publication date |
---|---|
EP4158645A4 (en) | 2023-11-22 |
US20220084432A1 (en) | 2022-03-17 |
JP2023531871A (ja) | 2023-07-26 |
JP7437496B2 (ja) | 2024-02-22 |
WO2021075641A1 (ko) | 2021-04-22 |
KR20230005909A (ko) | 2023-01-10 |
US11189192B2 (en) | 2021-11-30 |
TW202205311A (zh) | 2022-02-01 |
CN115699194A (zh) | 2023-02-03 |
EP4047617A1 (en) | 2022-08-24 |
EP4047617A4 (en) | 2022-12-07 |
WO2021241884A1 (en) | 2021-12-02 |
EP4158645A1 (en) | 2023-04-05 |
US20210118322A1 (en) | 2021-04-22 |
KR102250775B1 (ko) | 2021-05-11 |
US20210118544A1 (en) | 2021-04-22 |
KR20210046444A (ko) | 2021-04-28 |
JP2024055900A (ja) | 2024-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11734896B2 (en) | Augmented reality display system for evaluation and modification of neurological conditions, including visual processing and perception conditions | |
JP7437496B2 (ja) | 近視治療のためのデジタルシステム、デジタルシステムの動作方法及びコンピュータ読み取り可能媒体 | |
JP2021072885A (ja) | 機能を強化するために生理及び機械情報を結合する方法及びシステム | |
US20240122483A1 (en) | Artificial intelligence-based robotic system for physical therapy | |
US20210204853A1 (en) | Systems and Methods for Cognitive Diagnostics in Connection with Major Depressive Disorder and Response to Antidepressants | |
WO2021072084A1 (en) | Systems and methods for cognitive diagnostics for neurological disorders: parkinson's disease and comorbid depression | |
CN114762061A (zh) | 用于确定患者的风险评分的方法 | |
US20220384002A1 (en) | Correlating Health Conditions with Behaviors for Treatment Programs in Neurohumoral Behavioral Therapy | |
JP2023530624A (ja) | 心的外傷後ストレス障害(ptsd)および恐怖症の治療のためのシステムおよび方法 | |
KR20210046610A (ko) | 근시 치료를 위한 디지털 장치 및 애플리케이션 | |
CA3188330A1 (en) | Training system with interaction assist feature, training arrangement and training | |
Streck et al. | neomento SAD-VR treatment for social anxiety | |
De Jonge | Personalised relaxation therapy in Virtual Reality | |
US20220230755A1 (en) | Systems and Methods for Cognitive Diagnostics for Neurological Disorders: Parkinson's Disease and Comorbid Depression | |
KR20240006129A (ko) | 마사지 처방 장치 및 방법 | |
CN117982322A (zh) | 用于改善视力的数字装置以及应用程序 | |
Davies | Exploring personalised virtual reality experiences using real-time user-tracking data in application to loneliness interventions | |
KR20240049355A (ko) | 가상 통합 원격 비서 장치 및 방법 | |
Getzoff et al. | Brain–computer interface devices for patients with paralysis and amputation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220415 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230316 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20230615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230728 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240112 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240209 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7437496 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |